Surgical Resection of Metastatic Liver Tumors

Kavolius, Jeffrey; Fong, Yuman; Blumgart, Leslie H.

doi:10.1016/s1055-3207(18)30385-5

Cited by 62 publications

(32 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The liver is a preferential site of metastasis from a variety of tumors, such as colon cancer, breast carcinoma, and melanoma (3). In liver metastasis, the local host stroma, a complex mixture of fibroblasts, myofibroblasts, endothelial cells, and inflammatory cells, is considered to play a crucial role in the infiltration and colonization of the organ by metastatic cells, such that the outcome of metastasis depends on multiple interactions of metastatic cells with the stromal cells in the liver microenvironment (4).…”

Section: Introductionmentioning

confidence: 99%

A Secreted Form of ADAM9 Promotes Carcinoma Invasion through Tumor-Stromal Interactions

et al. 2005

View full text Add to dashboard Cite

Tumor cell invasion is a process regulated by integrins, matrix-degrading enzymes, and interactions with host tissue stromal cells. The ADAM family of proteins plays an important role in modulating various cellular responses. Here, we show that an alternatively spliced variant of ADAM9 is secreted by hepatic stellate cells and promotes carcinoma invasion. ADAM9-S induced a highly invasive phenotype in several human tumor cell lines in Matrigel assays, and the protease activity of ADAM9-S was required for invasion. ADAM9-S binds directly to A 6 B 4 and A 2 B 1 integrins on the surface of colon carcinoma cells through the disintegrin domain. ADAM9-S was also able to cleave laminin and promote invasion. Analysis of human liver metastases revealed that ADAM9 is expressed by stromal liver myofibroblasts, particularly those that are localized within the tumor stroma at the invasive front. These results emphasize the importance of tumor-stromal interactions in invasion and suggest that ADAM9-S can be an important determinant in the ability of cancer cells to invade and colonize the liver. (Cancer Res 2005; 65(11): 4728-38)

show abstract

Section: Introductionmentioning

confidence: 99%

A Secreted Form of ADAM9 Promotes Carcinoma Invasion through Tumor-Stromal Interactions

et al. 2005

View full text Add to dashboard Cite

show abstract

“…17,18 Unfortunately, only less than 10% of patients with liver metastasis are potential candidates for curative resection. 17,18 Moreover, the presence of disseminated tumor cells undetectable using current diagnostic methods frequently leads to tumor relapse after complete resection. [19][20][21] Thus, strategies for treating liver metastasis are highly desirable.…”

Section: Discussionmentioning

confidence: 99%

Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter

et al. 2004

View full text Add to dashboard Cite

Local and locoregional administration of adenovectors expressing the tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) gene has been demonstrated to be useful in treating established tumors in animals. Moreover, expression of the TRAIL gene from the human telomerase reverse transcriptase (hTERT) promoter can be used to prevent possible liver toxicity of the TRAIL gene. However, it remains unknown whether systemic administration of the TRAIL-expressing adenovector can be used for cancer therapy. Here, we showed that a combination of TRAIL gene therapy and gemcitabine, the first-line chemotheraphy agent for pancreatic cancer, had a synergistic effect on the induction of apoptosis in human pancreatic cancer cell lines in vitro. Systemic administration of an adenovector that contains an insertion of integrin-binding motif argine-glycine-aspartate (RGD) in the HI loop of the adenoviral fiber protein and expresses the human TRAIL gene from the hTERT promoter (designated Ad/TRAIL-F/RGD) suppressed the growth of human pancreatic tumor cells inoculated in the liver of nu/nu nude mice. Furthermore, Ad/TRAIL-F/RGD in combination with gemcitabine suppressed the tumor growth of pancreatic cancer in the liver more than did treatments consisting of each agent alone. No obvious liver toxicity was detected in any of the treatment groups. Our results suggest that TRAIL gene therapy in combination with gemcitabine might be a useful therapeutic approach for treating metastatic pancreatic cancers.

show abstract

“…[1] Surgical resection of these liver metastases has shown to improve 5-year survival of colorectal cancer (CRC) patients to about 30% (range 15-67%), but only 20% of patients are considered eligible for this surgical procedure. [2;3] If the metastases are not resectable, radiofrequency ablation (RFA) is a suitable alternative.…”

Section: Introductionmentioning

confidence: 99%

Adjuvant radioimmunotherapy after radiofrequency ablation of colorectal liver metastases in an experimental model

Jong

Hendriks

Franssen

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Surgical Resection of Metastatic Liver Tumors

Cited by 62 publications

References 45 publications

A Secreted Form of ADAM9 Promotes Carcinoma Invasion through Tumor-Stromal Interactions

A Secreted Form of ADAM9 Promotes Carcinoma Invasion through Tumor-Stromal Interactions

Suppression of pancreatic tumor growth in the liver by systemic administration of the TRAIL gene driven by the hTERT promoter

Adjuvant radioimmunotherapy after radiofrequency ablation of colorectal liver metastases in an experimental model

Contact Info

Product

Resources

About